Send me real-time posts from this site at my email

Feb. 18 - Trading List: Updates, Analyst Actions, Our Take - CRWD, HZNP

Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.

Crowdstrike price target raised to $270 from $205 at Mizuho

Mizuho analyst Gregg Moskowitz raised the firm's price target on Crowdstrike to $270 from $205 and keeps a Buy rating on the shares. The analyst's recent checks indicate healthy overall demand trends for software through January. Companies that enable digitization are still leading the way, although many legacy and/ or on-premises technologies continue to normalize, Moskowitz tells investors in a research note.

Crowdstrike resumed with a Hold at Stifel

Stifel analyst Brad Reback resumed coverage of Crowdstrike with a Hold rating and $240 price target. While he believes Crowdstrike "remains in the relative infancy of its opportunity to leverage the competitive superiority of the Falcon Platform," and believes the company's competitive moat should grow increasingly defined over time, Reback sees the current valuation at the high-end of its historical range limiting the potential for near-term appreciation in the stock, he tells investors.

Our Take:  "Great growth name in the right business. We have liked this one since it was just $80 bucks. Still a good growth stock and will continue to do well. But, we also agree with Stifel, use some caution as the valuation has gotten a bit high. So buy dips and sell covered calls on peaks".

$CRWD, CrowdStrike Holdings, Inc. / H1

Horizon Therapeutics price target raised to $120 from $103 at Jefferies

Jefferies analyst David Steinberg raised the firm's price target on Horizon Therapeutics (HZNP) to $120 from $103 and keeps a Buy rating on the shares, telling investors that he sees "a real likelihood for upgrades" to Horizon's multiple as Viela Bio's (VIE) R&D portfolio should accelerate the growth profile. In addition, recently launched Uplizna could emerge as Horizon's "next major franchise," with potential peak sales exceeding $1B across three indications, said Steinberg.

Our Take:  "HZNP has been a great growth performer for a couple of years now and it looks like the growth will continue. A good buy in the biotech/drug space".

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue